Botanix Pharmaceuticals Limited (ASX:BOT)

Market Cap	791.35M
Revenue (ttm)	2.07M
Net Income (ttm)	-39.29M
Shares Out	1.95B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,417,858
Average Volume	9,710,652
Open	0.4150
Previous Close	0.4050
Day's Range	0.3950 - 0.4400
52-Week Range	0.2525 - 0.5350
Beta	0.85
RSI	43.96
Earnings Date	May 26, 2025

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphyloc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 11
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BOT

Financial Performance

In 2024, Botanix Pharmaceuticals's revenue was 2.07 million, a decrease of -45.14% compared to the previous year's 3.77 million. Losses were -13.87 million, 51.5% more than in 2023.